HOME >> BIOLOGY >> NEWS
Jefferson scientists use gene therapy to restore function of damaged heart cells in lab

Researchers at Jefferson Medical College and Duke University have used gene therapy to help damaged heart cells regain strength and beat normally again in the laboratory. The work takes the scientists one step closer to eventual clinical trials in humans.

Walter Koch, Ph.D., director of the Center for Translational Medicine of the Department of Medicine at Jefferson Medical College of Thomas Jefferson University in Philadelphia, and his colleagues at Duke used a virus to carry a gene into the heart cells of individuals who had suffered from congestive heart failure. The gene introduced into these heart cells blocks the activity of an enzyme that is increased in failing human hearts and which contributes to the loss of the heart's contractile strength during the development of heart failure. When the activity of this enzyme is blocked by the gene therapy, the heart cells were able to contract at normal strength and their overall performance was improved.

Dr. Koch and his co-workers at Duke University Medical Center in Durham, N.C., report their findings April 6, 2004, in Circulation, a journal of the American Heart Association.

According to Dr. Koch, who is W.W. Smith Professor of Medicine at Jefferson Medical College of Thomas Jefferson University, researchers have known for some time that the beta-adrenergic receptor system fails to work properly in individuals with congestive heart failure. Such receptors "drive the heart both by rate and force of contraction," he says.

The researchers' target has been the beta-adrenergic kinase (ARK1), an enzyme that is elevated in human heart failure. One of its functions is to turn off beta-adrenergic receptors. "In heart failure, beta adrenergic receptor density is decreased, ARK is increased and both together cause dysfunctional beta receptor signaling," Dr. Koch says. "A failing heart then has little capacity to respond to exercise or stress because there are fewer receptors and the remaining rec
'"/>


5-Apr-2004


Page: 1 2

Related biology news :

1. Jefferson Lab detector technology aids development of cystic fibrosis therapy
2. Jefferson scientists find gene expression pattern may predict behavior of leukemia
3. Jefferson researchers develop microchip to track genetic signature of cancer and normal tissue
4. Jefferson researchers uncover biochemical clues to how cells migrate in embryos
5. Jefferson and Brigham and Womens researchers find blue light important for setting biological clock
6. Jefferson Lab experiment generates THz radiation 20,000 times brighter than anyone else
7. Jefferson scientists show neural stem cells can become dopamine-making brain cells in laboratory
8. Jefferson scientists show how collagen gene mutation leads to osteoarthritis
9. Jefferson scientists use gene repair technique to change albino mice hairs to black
10. Jefferson scientists show drug is effective against a Hepatitis C Virus model in the laboratory
11. Jefferson scientists propose mechanism to control the bodys red blood cell and platelet production

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/3/2020)... (PRWEB) , ... March 03, 2020 , ... Amplify Surgical, ... with the dualX Expanding Interbody Fusion System. , The landmark case was ... After the case Dr. Najafi noted, “dualX has completely changed the game for ...
(Date:3/2/2020)... , ... March 02, 2020 , ... Philadelphia IP law ... Bliss, Ph.D., J.D. has joined the firm as a Partner, and Stephany G. Small, ... an experienced patent attorney and will be a partner in the firm’s biotechnology and ...
(Date:2/28/2020)... ... , ... Meridian Clinical Research , a leading investigative research network, is ... Best Clinical Trial Site. Meridian is also the largest member of Platinum Research ... nominations were the result of two voting rounds, and winners will be announced at ...
Breaking Biology News(10 mins):
(Date:3/10/2020)... ... March 10, 2020 , ... Ortho Clinical Diagnostics, a global leader ... announced its ORTHOTM Sera, ID-MTS, a suite of extended antigen in a gel testing ... run on ORTHO VISION® and ORTHO VISION® Max in the United States and Canada. ...
(Date:3/4/2020)... ... March 04, 2020 , ... ... recombinant antibody products and services, today announced the launch of its FleXpress™ ... express a large number of antibodies at 80 ml scale. All production ...
(Date:3/3/2020)... , ... March 03, 2020 , ... ... invited to present the latest breast implant technology at the IMCAS Innovation Shark ... new innovations in the dermatology, plastic surgery, and aesthetic science industries that promise ...
(Date:2/26/2020)... ... February 25, 2020 , ... Continuing its leading ... the results of its safety assessment on the biotechnologically produced 3-Fucolsyllactose (3-FL) HMO. ... milk. These complex carbohydrates are indigestible and therefore function as a prebiotic by ...
Breaking Biology Technology:
Cached News: